Navigation Links
Biodel Reports Second Quarter Fiscal Year 2011 Financial Results
Date:5/5/2011

Business Review

  • Biodel has selected two new recombinant human insulin-based formulation candidates, BIOD-105 and BIOD-107, for clinical development as ultra-rapid-acting mealtime insulins for the treatment of diabetes.  Following recent discussions with the U.S. Food and Drug Administration, Biodel now plans to accelerate the timelines for clinical testing of these new formulations.
  • Biodel has initiated a Phase 1 trial of BIOD-105 and BIOD-107 in a double-blind, three-period cross-over study in patients with Type 1 diabetes.  This trial will evaluate the pharmacokinetic, pharmacodynamic and injection site tolerability profiles of the two experimental insulins relative to Humalog® when delivered by subcutaneous injection.  
  • In parallel with the Phase 1 clinical trial of BIOD-105 and BIOD-107 described above, investigators at Oregon Health and Sciences University will soon initiate a similar comparative study evaluating the use of these formulations and Humalog® when delivered by insulin pumps.  The results of the two Phase 1 trials will be used to select the best formulation for Phase 2 clinical testing, planned to initiate later this year and Phase 3 clinical testing planned to initiate in 2012.
  • Biodel recently named Dr. Brian Pereira as chairman of the company's board of directors.  Dr. Pereira has been a board member since November 2007 and, as an experienced biotechnology executive, brings invaluable expertise to the company.  Former chairman Dr. Charles Sanders will remain a member of Biodel's board.

  • Conference Call and Webcast Information

    Biodel's senior management will host a conference call on May 5, 2011, beginning at 4:30 pm Eastern Daylight Saving Time, to discuss these results and provide a company update. Live audio of the conference call will be available to investors, members of the news media and the general public by dialing 1-877-303-8028 (United States)
    '/>"/>

    SOURCE Biodel Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Biodel to Report Second Quarter Fiscal Year 2011 Financial Results on May 5, 2011
    2. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
    3. Biodel Announces Appointment of Dr. Brian J.G. Pereira as Board Chairman; Dr. Charles A. Sanders to Remain on Board
    4. Biodel Announces Accelerated Development Plan for Ultra-Rapid-Acting Insulins: Initiate Phase 2 in 2011; Phase 3 Pivotal Trials in 2012
    5. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
    6. Biodel Inc. to Present at the Roth 23rd Annual OC Growth Stock Conference on March 16, 2011
    7. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
    8. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
    9. Biodel Reports First Quarter Fiscal Year 2011 Financial Results
    10. Biodel to Report First Quarter Fiscal Year 2011 Financial Results on February 3, 2011
    11. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... Sept. 18, 2014   MacPractice,s MacPractice MD ... Complete EHR certification, which designates that the software is ... 1 and Stage 2 Meaningful Use measures required to ... Act (ARRA).  MacPractice MD MU version 5.0 was certified ... an Office of the National Coordinator-Authorized Certification Body (ONC-ACB) ...
    (Date:9/18/2014)... --This BCC Research report discusses the medical device technologies in ... size, and opportunities for different devices and regions. It includes ... in the report focuses on technological trends in recent years ... and Japan . ... medical device technologies market. - Analyze market structure, including segments ...
    (Date:9/18/2014)... , Sept. 18, 2014  KIYATEC announced ... million Small Business Innovation Research (SBIR) Phase II ... of the 27 institutes and centers that comprise ... course of the two year award, KIYATEC will ... two issues at the forefront of cancer therapy ...
    Breaking Medicine Technology:MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3
    ... March 2007 - Cancer drug,developer Antisoma plc (LSE: ... from its second, confirmatory phase II,trial of AS1404 ... trial tested an 1800 mg/m2 dose of AS1404 ... response rate of 50%. A further 43% of,patients ...
    ... BioSciences,Inc., a specialty dermatology company, today announced the,publication of ... the journal,Cell by its co-founder and board member, David ... an important protein,p53, in the pigmentation of skin. Fisher's ... tumor suppressor in other cancers in,the body, p53 also ...
    Cached Medicine Technology:Antisoma plc (UK) - Second lung cancer trial adds to positive data,on AS1404 2Antisoma plc (UK) - Second lung cancer trial adds to positive data,on AS1404 3Study in Cell by Magen BioSciences Co-Founder David E. Fisher,Identifies New Roles in Skin Cancer Prevention for Key Tumor,Suppressor Protein 2
    (Date:9/18/2014)... September 18, 2014 Alexandria, VA — ... today that 10 more communities have joined the growing ... health department accreditation. The decisions bring the number of ... 54. PHAB is the non-profit organization that administers the ... and protect the health of the public by advancing ...
    (Date:9/18/2014)... 18, 2014 (HealthDay News) -- Rising temperatures in the ... spread to shallow waters that are becoming warmer, an ... reefs, ecologists report. A study of 40 species ... northward movement by the invasive and poisonous lionfish, according ... (NOAA) and the University of North Carolina-Wilmington, who published ...
    (Date:9/18/2014)... "Medical staff need better ways to ... the patient's privacy," said one of two inventors from ... order to supply caregivers with the equipment they need ... prototype for The Helper to make it easier to ... patient onto his or her side. It also securely ...
    (Date:9/18/2014)... One of the most capable and sophisticated ... ShandsCair Flight Program’s new EC155 B1, will be ... the Air Medical Transport Conference (AMTC), Sept. 22-24, in ... service ShandsCair EC155 and the Vanderbilt University LifeFlight ... highlight Airbus Helicopters broad, industry leading line-up of ...
    (Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 (HealthDay ... patients seeking care at larger urban hospitals are likely to ... at smaller or more rural facilities, new research suggests. ... emergency care varies dramatically across hospitals in the United States," ... Renee Hsia, an associate professor at the University of California, ...
    Breaking Medicine News(10 mins):Health News:Ten More Communities Reaping Benefits of National Accreditation 2Health News:Ten More Communities Reaping Benefits of National Accreditation 3Health News:Ten More Communities Reaping Benefits of National Accreditation 4Health News:Rising Atlantic Ocean Temperatures Could Pose Threat to Reefs 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:ER Waiting Times Vary Significantly, Studies Find 2Health News:ER Waiting Times Vary Significantly, Studies Find 3
    ... ... a clinical trial that is testing whether specialized contact lenses can slow or halt ... and Robert Davis, working with EyeVis Eye and Vision Research Institute, recently reported on ... , ...
    ... Family Research Council President Tony Perkins responded to ... Obama,s executive order for federal funding of human embryonic ... the NIH guidelines remove life-protecting limits on federal funding ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO ) ...
    ... ... a national leader in accounts receivable management, and collection services to the healthcare industry has ... in Vero Beach, Florida. , ... Vero Beach, FL (PRWEB) July 7, 2009 -- National healthcare receivables industry leader, Medical ...
    ... a Woman,s Right to Choose , , ARLINGTON ... breast reconstruction procedures performed in 2008, nearly 70 percent ... not informed of the reconstructive options available to them, ... by the American Society of Plastic Surgeons (ASPS) shows ...
    ... July 7 The Anthropedia Foundation, a non-profit organization ... Know Yourself , an innovative DVD series designed ... and healthier lives. The series is a step-by-step guide ... part focuses on straightforward concepts and simple exercises that ...
    ... sellers appears to reduce the trafficking of guns to ... the Johns Hopkins Bloomberg School of Public Health. Preventing ... 85 percent of guns recovered by police were recovered ... of the guns according to prior research from the ...
    Cached Medicine News:Health News:Can a Contact Lens Cure Nearsightedness? Five-Year Clinical Study Testing Corneal Reshaping Therapy as Possible Method to Arrest Myopia 2Health News:Can a Contact Lens Cure Nearsightedness? Five-Year Clinical Study Testing Corneal Reshaping Therapy as Possible Method to Arrest Myopia 3Health News:NIH Stem Cell Guidelines Ethically Irresponsible, Scientifically Unworthy, Useless to Patients, Says Family Research Council 2Health News:Medical Data Systems, Inc. (MDS) Announces Operations Expansion and Opening of its Primary Collections Operations Office 2Health News:Medical Data Systems, Inc. (MDS) Announces Operations Expansion and Opening of its Primary Collections Operations Office 3Health News:Are Breast Cancer Patients Being Kept In The Dark? 2Health News:Knowing Yourself Can Improve Your Health and Happiness 2Health News:Knowing Yourself Can Improve Your Health and Happiness 3Health News:Regulation and oversight of gun sales reduces trafficking to criminals 2Health News:Regulation and oversight of gun sales reduces trafficking to criminals 3
    ... autoimmune testing feature single-well ANA screen and ... reflex tests including dsDNA, and 6 individual ... (La), Scl-70 and Jo-1. In addition, our ... of products for Cardiolipins (IgA, IgG, IgM), ...
    ... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: